Seven insiders at DexCom, Inc. (NASDAQ:DXCM) have recently performed transactions at the company. Richard Doubleday, Sr. Vp. Worldwide Sales at DexCom, Inc. sold 2,228 shares of Common Stock, at a Price of $ 43.23 per share. Following this transaction, Mr. Doubleday owns 124,354 shares at the Company, in a direct form. Sr. Vp, General Counsel, John Lister, sold another 2,879 shares of common stock at the same price, and currently holds, directly, 109,676 securities at the company. Moreover, Vp and Cfo Jess Roper reported selling 2,228 securities at the company, at a Price of $ 43.23 per share. Currently, Mr. Roper owns 85,985 shares at the company, in a direct form. In addition, President and Coo, Kevin Sayer and Evp, Strategy & Corp. Dev. Robert Steven Pacelli, sold, respectively, 10,861 shares, and 6,225 shares, at the same average weighted Price of $43.23 per share. Following this transaction, Mr. Sayer owns 414,063 shares at the company, in a direct form, and Mr. Pacelli currently holds 235,174 company shares, directly. All of these shares were sold pursuant to Rule 16b-3(e), to cover the Company’s tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.
Moreover, Jeffrey Moy, Svp, Operations at this $ 3.21 Billion Market Cap medical device company, acquired 15,624 shares of Common Company Stock, at prices ranging from $ 43.23 to $ 43.36 per share. The shares were transferred from direct ownership to ownership under the Moy Family Trust upon vesting of previously awarded restricted stock units. Mr. Moy also reported selling another 8,206 shares of common stock, at an average price of $ 43.30 per share. These shares were sold to cover the Company’s tax withholding obligation. Following these transactions, Mr. Moy holds 154,080 shares indirectly, by Trust, and another 82,292 securities, in a direct form. Svp, Regulatory And Clinical, Andrew Balo acquired 10,000 shares of common stock, at a Price of $ 7.63 per share. The transaction was made as “Exercise or conversion of derivative security exempted pursuant to Rule 16b-3,” (SEC). Moreover, Mr. Balo sold 14,671 shares of DexCom, Inc. (NASDAQ:DXCM)’s common stock, at prices ranging from $ 43.23 to $ 42.97 each share. Of this amount, 4,671 shares were sold to cover the Company’s tax withholding obligation, and the remaining 10,000 were sold as open market or private sale of non-derivative or derivative security. After the reported transactions, Mr. Balo holds 154,534 company shares.